Abstract Session 5: Immune Therapies

Co-Chair(s)

• 

  Katja Weisel, MD (she/her/hers)

  Deputy Director
  University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
  Hamburg, Germany
• 

  Simon Harrison, MBBS, MRCP(uk), FRCPath(uk), FRACP, PhD (he/him/his)

  Director, Centre of Excellence in Cellular Immunotherapy
  Peter MacCallum Cancer Centre
  Melbourne, Australia

Presentations:

• 4:30 PM – 4:42 PM EEST

  OA-05: Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): analysis of patient- and disease-related factors associated with responses
  

  Speaker: Simon J. Harrison, MBBS, MRCP(uk), FRCPath(uk), FRACP, PhD (he/him/his) – Peter MacCallum Cancer Centre
• 4:42 PM – 4:54 PM EEST

  OA-55: Real world experience of patients treated with teclistamab: a BCMA-directed bispecific t-cell engaging therapy for multiple myeloma
  

  Speaker: Shonali Midha, MD – Dana Farber Cancer Institute
• 4:54 PM – 5:06 PM EEST

  OA-47: Additional analysis of CARTITUDE-4: Cilta-cel vs standard of care (PVd or DPd) in lenalidomide-refractory patients with multiple myeloma and 1-3 prior lines of therapy
  

  Speaker: Salomon Manier, MD, PhD – Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France
• 5:06 PM – 5:18 PM EEST

  OA-08: GPRC5D-Targeted CAR-T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma Progressing after or Refractory to BCMA CAR-T cell therapy: Updated Results from a Phase 2 Clinical Trial
  

  Speaker: Jieyun Xia, MD – The Affiliated Hospital of Xuzhou Medical University
• 5:18 PM – 5:30 PM EEST

  OA-34: Feasibility of a novel academic anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory AL amyloidosis
  

  Speaker: Eyal Lebel, MD – Hadassah medical center